Journal
CURRENT RHEUMATOLOGY REPORTS
Volume 17, Issue 9, Pages -Publisher
SPRINGER
DOI: 10.1007/s11926-015-0535-y
Keywords
Assessment of SpondyloArthritis international Society (ASAS); ASAS classification criteria; Spondyloarthritis (SpA); Axial spondyloarthritis (axSpA); Ankylosing spondylitis (AS)
Categories
Funding
- AbbVie
- MSD
- Pfizer
- UCB
- Janssen
- Leo Pharma
- Novartis
- Amgen
- Celgene
- Crescendo Bioscience
Ask authors/readers for more resources
Classification criteria should facilitate selection of similar patients for clinical and epidemiologic studies, therapeutic trials, and research on etiopathogenesis to enable comparison of results across studies from different centers. We critically appraise the validity and performance of the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (axSpA). It is still debatable whether all patients fulfilling these criteria should be considered as having true axSpA. Patients with radiographically evident disease by the ASAS criteria are not necessarily identical with ankylosing spondylitis (AS) as classified by the modified New York criteria. The complex multi-arm selection design of the ASAS criteria induces considerable heterogeneity among patients so classified, and applying them in settings with a low prevalence of axial spondyloarthritis (SpA) greatly increases the proportion of subjects falsely classified as suffering from axial SpA. One of the unmet needs in nonradiographic form of axial SpA is to have reliable markers that can identify individuals at risk for progression to AS and thereby facilitate early intervention trials designed to prevent such progression. We suggest needed improvements of the ASAS criteria for axSpA, as all criteria sets should be regarded as dynamic concepts open to modifications or updates as our knowledge advances.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available